

Pregabalin: A guide to its use in fibromyalgia, neuropathic pain and generalized anxiety disorder

Article in *Drugs & Therapy Perspectives* 30(3):75-84 · February 2014
DOI: 10.1007/s40267-014-0107-7



1st Katherine A. Lyseng-Williamson

Abstract

Pregabalin has a multidimensional effect across a range of disorders that have of a pathogenesis involving a CNS response of abnormal hyperexcitability. The high-affinity binding of pregabalin at $\alpha 2\delta$ proteins and the subsequent reduction in excessive release of several excitatory neurotransmitters appears to be responsible for the clinical benefits of pregabalin in treating fibromyalgia, neurological pain and generalized anxiety disorder. The use of pregabalin in these complex and difficult-to-treat conditions is associated with rapid and durable clinically significant improvements in several outcome measures relating to core symptoms, including pain, anxiety and sleep, and improvements in overall health status and health-related quality-of-life. The most common adverse events associated with the drug are dizziness and somnolence, which are generally mild to moderate in intensity and are tolerated by many patients.

Do you want to read this article?

Request the full-text to ask the author to provide the full-text version.

Full-text requested

Now you can discuss publications directly with the authors and other experts by adding your comments here.

Citations 0 **References 45** Comments Add yours

Carville, S. F. et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. *Ann. Rheum. Dis.* 67, 536-541

Full-text Article · May 2008 · *Annals of the rheumatic diseases*

S F Carville S Arendt-Nielsen H Bliddal +16 more authors... E H Choy

Read full-text

0 Comments 458 Citations

See all >
0 Citations

See all >
10 Reads

Following


Full-text requested

Read full-text

0 Comments 18 Citations

Spinal Cord Injury Pain: Mechanisms and Management

Article · Mar 2012 · Current Pain and Headache Reports





 Nanna Brix Finnerup  Cathrine Baastup

Request full-text

0 Comments 64 Citations

Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment

Full-text Article · Nov 2012 · Pain Research and Treatment

 Enrico Bellato  Eleonora Marini  Filippo Castoldi +3 more authors...  Davide Blonna

Read full-text

0 Comments 46 Citations

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17:9

Full-text Article · Sep 2010 · European Journal of Neurology





 N Attal  G Cruccu  R Baron +3 more authors...  T Nurmikko

Read full-text

0 Comments 793 Citations

Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin

Full-text Article · Jun 2008 · Pain




 Leslie J Crofford  Philip J Mease  Susan L Simpson +3 more authors...  Uma Sharma

Read full-text

0 Comments 187 Citations

Neuropathic pain

Full-text Article · Aug 2013 · Current opinion in anaesthesiology




 Robert W Hurley  Meredith C.B. Adams  Honorio T Benzon

Read full-text

0 Comments 7 Citations

Evidence-based pharmacological treatment of generalized anxiety disorder

Full-text Article · Jun 2011 · The International Journal of Neuropsychopharmacology

 David S Baldwin  Sarah Waldman  Christer Allgulander

Read full-text

0 Comments 62 Citations

See all >
0 Citations

See all >
10 Reads

Following

Full-text requested

Request full-text

0 Comments 15 Citations

Pregabalin 1008–105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial

Full-text Article · Apr 2005 · Arthritis & Rheumatology

 Leslie J Crofford  Michael C Rowbotham  Philip J Mease +6 more authors...  Uma Sharma

Read full-text

0 Comments 446 Citations

Show more

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

This publication is classified Romeo Green. [Learn more](#)

© 2008-2016 researchgate.net. All rights reserved.

[About us](#) · [Contact us](#) · [Careers](#) · [Developers](#) · [News](#) · [Help Center](#) · [Privacy](#) · [Terms](#) | [Advertising](#) · [Recruiting](#)